Please login to the form below

Not currently logged in
Email:
Password:

Avanir Pharmaceuticals appoints new president and CEO

Rohan Palekar succeeds Keith Katkin

US-based biopharmaceutical firm Avanir Pharmaceuticals has appointed Rohan Palekar as its new president and chief executive officer.

He will be responsible for overseeing the development of the company's pipeline of products for CNS disorders along with the commercialisation of its recently FDA-approved neurological product, Nuedexta.

Palekar joined Avanir as senior vice president and chief commercial officer in March 2012 and was promoted to executive vice president and chief operating officer three years later.

He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson & Johnson and Centocor.

Palekar replaces Keith Katkin who served as president and chief executive officer for Avanir from March 2007 and will continue on at the company as a member of its board of directors.

Katkin said: “After nearly a decade of serving as Avanir's president and chief executive officer, I am incredibly proud of what we have accomplished and how much we have grown, transitioning from a development to a commercial organisation.

“I am very pleased to be transitioning to this new role and handing the reins to Roham, a passionate and innovative leader who ... has made significant contributions since joining Avanir over three years ago.”

25th January 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics